Research Papers

This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.

Displaying 148 papers

Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase

10/2009 - Haque TS, Liang N, Golla R, et. al. Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5872-6. doi: 10.1016/j.bmcl.2009.08.077.

Tags: Drug Discovery, Drug Targets, Preclinical Data

Synthesis and Structure-activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains

9/2009 - Sutherland HS, Blaser A, Kmentova I, et. al. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J Med Chem. 2010 Jan 28;53(2):855-66. doi: 10.1021/jm901378u.

Tags: Drug Discovery, Pharmacokinetics, Preclinical Data

Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on

6/2009 - Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother. 2009 Sep;53(9):3726-33. doi: 10.1128/AAC.00112-09

Tags: Advocacy, Clinical Development, Clinical Trial Results, Pretomanid/PA-824

Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects

6/2009 - Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman, MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother. 2009 Sep;53(9):3720-5. doi: 10.1128/AAC.00106-09.

Tags: Clinical Development, Clinical Trial Results, Pharmacodynamics, Pretomanid/PA-824

Acid Resistance in Mycobacterium tuberculosis

5/2009 - Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09.

Tags: Advocacy, Drug Discovery, Drug Targets, M.tb. Biology

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis

2/2009 - Rosenthal IM, Tasneen R, Peloquin CA, et. al. Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2012 Aug; 56(8): 4331–4340. doi: 10.1128/AAC.00912-12

Tags: Drug Discovery, Editorials, Global Pipeline, HRZE, Preclinical Data, Preclinical Models, Pyrazinamide, Rifapentine

Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug PA-824

2/2009 - Thompson AM, Blaser A, Anderson RF, et. al. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J

Tags: Drug Discovery, Pharmacokinetics, Preclinical Data

Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment

11/2008 - Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol. 2009 Jan;191(2):625-31. doi: 1

Tags: Drug Discovery, Drug Targets, M.tb. Biology

Estimating the market for tuberculosis drugs in industrialized and developing nations

10/2008 - Schwalbe NR, Wells WA, Geaneotes AP, et. al. Estimating the market for tuberculosis drugs in industrialized and developing nations. Int J Tuberc Lung Dis. 2008 Oct;12(10):1173-81. http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000010/a

Tags: Regimen Change, TB Burden, TB Drug Market, TB Market

Emerging Drugs for Active Tuberculosis

10/2008 - Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med. 2008 Oct;29(5):552-9. doi: 10.1055/s-0028-1085706.

Tags: Bedaquiline (TMC-207), Clinical Development, Drug Discovery, Editorials, Global Pipeline, Pretomanid/PA-824, Rifapentine

Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1

5/2008 - Wang H, Ruan Z, Li JJ, et. al. Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3168-72. doi: 10.1016/j.bmcl.2008.

Tags: Drug Discovery, Drug Targets, Preclinical Data

Timing of Default From Tuberculosis Treatment: A Systematic Review

5/2008 - Kruk ME, Schwalbe NR, Aguiar CA. Timing of default from tuberculosis treatment: a systematic review. Trop Med Int Health. 2008 May;13(5):703-12. doi: 10.1111/j.1365-3156.2008.02042.x.

Tags: Advocacy, Policy, Regimen Change, TB Market

Handbook of anti-tuberculosis agents

3/2008 - Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008 Mar;88(2):85-6. doi: 10.1016/S1472-9792(08)70002-7.

Tags: Clinical Development, Clofazamine, Global Pipeline, HRZE, Linezolid, Moxifloxacin, Pharmacodynamics, Pharmacokinetics, Pyrazinamide, Rifapentine, Sutezolid

The ethics of non-inferiority trials

3/2008 - Nunn AJ, Meredith SK, Spigelman MK, Ginsberg AM, Gillespie SH. The ethics of non-inferiority trials. Lancet. 2008 Mar 15;371(9616):895; author reply 896-7. doi: 10.1016/S0140-6736(08)60404-3.

Tags: Advocacy, Clinical Development, Clinical Trial Results, Editorials, Policy, Trial Design

Advancing the science in clinical trials for new TB drugs

2/2008 - Wells WA, Brooks A. Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Health Res Policy Syst. 2011 Mar 31;9:15. doi: 10.1186/1478-4505-9-15.

Tags: Biomarkers, Clinical Development, Editorials, Moxifloxacin, Trial Design

New tuberculosis therapeutics: a growing pipeline

8/2007 - Spigelman MK New tuberculosis therapeutics: a growing pipeline. J Infect Dis. 2007 Aug 15;196 Suppl 1:S28-34. http://jid.oxfordjournals.org/content/196/Supplement_1/S28.long. Accessed March 7, 2016

Tags: Clinical Development, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Pretomanid/PA-824, Rifapentine, TB-HIV

Turning the tide on tuberculosis: a combined effort

7/2007 - Spigleman M. Turning the tide on tuberculosis: a combined effort. SciDevNet. 2007 4 Jul. http://www.scidev.net/global/health/opinion/turning-the-tide-on-tuberculosis-a-combined-effor.html. Accessed March 11, 2016

Mycobacterium tuberculosis DNA gyrase as a target for drug discovery

6/2007 - Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00008?token=00521b85a26b1174e1f7b76504c48662a2

Tags: Drug Discovery, Drug Targets, M.tb. Biology, MDR-TB, Preclinical Data

Challenges associated with current and future TB treatment

6/2007 - Laurenzi M, Ginsberg AM, Spigelman M. Challenges associated with current and future TB treatment. Infect Disord Drug Targets. 2007 Jun;7(2):105-19. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00004?token=004e1567d370e7e442f206

Author(s): Laurenzi, M., A. Ginsberg, and M. Spigelman

Tags: Advocacy, Clinical Development, Editorials, Global Pipeline, Trial Design

Planning to improve global health: the next decade of tuberculosis control

5/2007 - Dermot Maher, Chris Dye, Katherine Floyd, et. al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ. 2007 May; 85(5): 341–347. doi: 10.2471/06.037820

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB-HIV

Pages